Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age8-65
SponsorNemours Children's Clinic

About this trial

This R01 is in response to RFA-DK-19-021, Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes. The objective is to test the feasibility and acceptability of a novel, practical, and potentially scalable screen to treat program for diabetes distress in families of school-age children with T1D (called Remedy to Diabetes Distress \[R2D2\]) and to test the initial efficacy of R2D2 to reduce diabetes distress to improve children's glycemic control.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

child age between 8-12 years, physician confirmed T1D diagnosis,

either the child or the parent or both the child and parent report diabetes distress levels at or above clinical cut-points,

child is on an intensive insulin regimen (pump or MDI).

Disqualifiers

children on a conventional insulin regimen, children and/or parents who do not report diabetes distress levels at or above the clinical cut-points,

children who have an allergy or sensitivity to the adhesive and/or skin preparation used for CGM, children with a comorbid chronic condition (e.g., renal disease),

children and parents who do not speak English.

Trial design

Design model

Parallel

Treatments tested in this trial

  • R2D2 mHealth intervention

    Behavioral

    R2D2 mHealth treatment will use cognitive behavioral therapy, mindfulness, and behavioral activation strategies

Treatment groups

180 Participants
are divided into 2 treatment groups
Group A: R2D2 mHealth treatment for diabetes distressExperimental treatment 1 intervention
Group B: Standard Care ControlNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

youth glycated hemoglobin (HbA1c)

proxy measure of average glycemic levels over 10-12 weeks

Time frame
week 0, week 13
2

youth time in range

based on continuous glucose levels, the percentage of time spent between 70-180mg/dl

Time frame
week 0, week 13

Secondary outcomes

1

Problem Areas in Diabetes-Child (PAID-C)

validated child report of diabetes distress; range: 11-66, higher scores reflect greater distress

Time frame
week 0, week 13
2

Parent Problem Areas in Diabetes-Child (P-PAID-C)

validated parent report of diabetes distress; range 16-96, higher scores reflect greater distress

Time frame
week 0, week 13
3

Diabetes Strengths and Resilience

validated child report of resilience; range: 12-60, higher scores reflect greater resilience

Time frame
week 0, week 13
4

Brief Resilience Scale

validated adult report of resilience; range 1-5, higher scores reflect greater resilience

Time frame
week 0, week 13

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Nemours Children's Clinic

Lead sponsor

Children's Mercy Hospital Kansas City

Collaborator